Precigen's stock surged 8.67% in pre-market trading, driven by investor enthusiasm following the company's release of its first-quarter 2026 financial results after the previous market close.

The biopharmaceutical company reported revenue of $23.25 million, significantly beating analyst estimates of $20.80 million. This represents a dramatic year-over-year increase of over 1,600%, primarily driven by $21.6 million in sales from its newly launched product PAPZIMEOS, which received FDA approval in August 2025.

Precigen also reported a sharply narrowed net loss of $7.93 million compared to $54.2 million a year earlier. Management indicated that current cash reserves combined with anticipated PAPZIMEOS revenue should fund operations to cash flow break-even by the end of 2026, providing positive forward guidance to investors. Analyst sentiment remains bullish with a median price target of $9.50, representing significant upside potential from recent closing levels.